Colorectal Cancer – Marwan Fakih, MD, and Robert Figlin, MD, provide post ESMO ’19 clinical update

Colorectal Cancer – Marwan Fakih, MD, and Robert Figlin, MD, provide post ESMO ’19 clinical update

Monday October 28, 2019

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Marwan Fakih, MD, Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, discuss colorectal cancer clinical updates from ESMO 19

Breast Cancer – Sara Hurvitz, MD, and Robert Figlin, MD, discuss recent clinical developments in early stage and late stage breast cancer

Friday July 17, 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Sara Hurvitz, MD, Associate Professor of Medicine, Geffen School of Medicine, UCLA, Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit, discuss breast cancer patient types, challenges, and treatment advances.

Non Small Cell Lung Cancer (NSCLC) – Edward Garon, MD, and Robert Figlin, MD, discuss promising agents in development for the management of NSCLC from ASCO20

Thursday June 11, 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Edward Garon, MD, Director of Thoracic Oncology Program, Jonsson Comprehensive Cancer Center, Associate Professor of Medicine, David Geffen School of Medicine, UCLA, discuss promising agents in development for the management of NSCLC from ASCO20

Waldenstrom macroglobulinemia – Constantine Tam, MD, and Robert Figlin, MD, discuss recent clinical advances in the treatment of Waldenstrom macroglobulinemia from ASCO20

Monday June 8, 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Constantine Tam, MD, Haematologist and Disease Group Lead, Low Grade Lymphoma and Chronic Lymphocytic Leukemia, Peter MacCallum Cancer Centre, discuss the progress in Waldenstrom macroglobulinemia from ASCO20

Featured Videos

Sara Hurvitz, MD, discusses the recently announced results of Monarch E and PALLAS adjuvant trials

Dana Chase, MD, FACOG, on interpretations of the overall survival results of the Phase 3 SOLO2 study

Dana Chase, MD, FACOG, summarizes the outcomes of the NRG-GY004 phase III study in ovarian cancer